21+
Age Verification
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
This research blend combines two complementary peptides targeting the growth hormone axis through distinct mechanisms: CJC-1295 without DAC (modified GHRH 1-29 analogue, 5mg) and Ipamorelin (pentapeptide GHRP, 5mg). The combination of a growth hormone-releasing hormone analogue with a growth hormone-releasing peptide enables researchers to study the synergistic receptor engagement of both GHRH and ghrelin-receptor pathways simultaneously.
CJC-1295 without DAC (also known as Mod GRF 1-29) is a modified 29-amino acid GHRH analogue with four amino acid substitutions that enhance metabolic stability compared to the native GHRH peptide. Ipamorelin is a highly selective pentapeptide growth hormone secretagogue that binds the ghrelin receptor (GHS-R1a) without significantly affecting cortisol or prolactin levels in preclinical models.
AXOM CJC-1295 + Ipamorelin is manufactured under strict quality control protocols and verified to ≥99% purity per component via reverse-phase HPLC. Total peptide content is 10mg per vial (5mg each). For research and laboratory use only.
Complementary GHRH analogue and growth hormone secretagogue targeting two distinct receptor pathways for synergistic research applications.
CJC-1295 (No DAC) acts via the GHRH receptor while Ipamorelin engages the ghrelin receptor (GHS-R1a) — two independent signaling cascades.
≥99% HPLC-verified purity per component with full COA documentation. Every lot independently tested by third-party analytical laboratories.
Study characterizing the pharmacokinetic and pharmacodynamic profile of CJC-1295 in healthy subjects. Demonstrated prolonged GHRH receptor engagement and sustained elevation of GH and IGF-I levels, establishing the compound's extended activity profile compared to native GHRH.
Landmark study characterizing ipamorelin as the first growth hormone secretagogue to demonstrate high selectivity for GH release without concomitant effects on cortisol, prolactin, or aldosterone in preclinical models. Established the peptide's unique receptor binding selectivity profile among GHRP compounds.
Comprehensive review of growth hormone-releasing peptides and their receptor interactions. Discusses the synergistic relationship between GHRH and GHRP signaling pathways, documenting how combined receptor engagement produces amplified downstream effects compared to individual pathway activation.
| Product Name | CJC-1295 (No DAC) + Ipamorelin Research Blend |
| Total Content | 10mg per vial |
| Component 1 | CJC-1295 Without DAC (Mod GRF 1-29) — 5mg | CAS: 863288-34-0 | MW: ~3,367.97 Da |
| Component 2 | Ipamorelin (Pentapeptide GHRP) — 5mg | CAS: 170851-70-4 | MW: ~711.85 Da |
| CJC-1295 Sequence | Modified GHRH (1-29) with Ala-2, Gln-8, Ala-15, Leu-27 substitutions |
| Ipamorelin Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Receptor Targets | GHRH Receptor (CJC-1295) + GHS-R1a / Ghrelin Receptor (Ipamorelin) |
| Purity | ≥99% per component (Reverse-Phase HPLC) |
| Form | Lyophilized white powder |
| Solubility | Soluble in sterile water, bacteriostatic water |
| Endotoxin | <1 EU/μg (LAL method) |
| Certification | COA included with every order |
| Intended Use | For research and laboratory use only |
CJC-1295 + Ipamorelin is supplied as a lyophilized powder and should be reconstituted with sterile bacteriostatic water (BAC water) for research applications.
All orders ship within the continental United States via USPS or UPS. Peptides are shipped at ambient temperature — lyophilized peptides are stable during transit. Free shipping on orders over $250.
